Urogen Pharma SEC Filings

Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN), received and settled restricted stock units in September 2025. On 09/07/2025 1,667 RSUs vested, each representing one ordinary share, increasing his beneficial ownership to 149,896 shares. On 09/08/2025 he sold 871 shares at $19.11 to satisfy withholding tax obligations, leaving him with 149,025 shares beneficially owned. The RSUs granted on 09/07/2023 totalled 5,000 and vest in three equal annual installments beginning 09/07/2024. The Form 4 was signed by an attorney-in-fact on 09/09/2025.

Insider transactions at UroGen Pharma Ltd. (URGN): Jason D. Smith, General Counsel, had 3,333 restricted stock units (RSUs) vest on 09/07/2025, which converted into 3,333 ordinary shares. On 09/08/2025 he sold 1,520 shares at $19.11 each to satisfy withholding tax obligations following the RSU settlement. After these transactions the reporting person beneficially owned 43,305 ordinary shares. The RSU grant referenced was originally for 10,000 shares, granted 09/07/2023 and vesting in three equal annual installments beginning 09/07/2024.

Form 144 notice for UroGen Pharma Ltd. (URGN) reports a proposed sale of 871 ordinary shares through Oppenheimer & Co. on 09/08/2025 with an aggregate market value of $16,444.48. The shares were acquired as RSUs on 09/07/2023 totaling 3,333 units for this grant, with payment recorded on the acquisition date. The filing also discloses two prior ordinary-share sales by the same seller in the past three months: 5,149 shares on 07/28/2025 for $98,551.86 and 5,162 shares on 06/09/2025 for $38,043.94. The filer affirms no undisclosed material adverse information about the issuer.

UroGen Pharma Ltd. (URGN) filing a Form 144 notifies a proposed sale of 1,520 ordinary shares through Oppenheimer with an aggregate market value of $28,697.60, scheduled approximately for 09/08/2025. The shares were acquired as RSUs on 09/07/2023 (6,666 units reported acquired at that time). The filer also reported a prior sale on 07/28/2025 of 7,522 ordinary shares generating $143,971.08 in gross proceeds. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer. The form identifies the broker as Oppenheimer and shows ~46.26 million shares outstanding for the issuer.

UroGen Pharma insider grant: Director Daniel George was granted equity awards on 08/26/2025 consisting of a stock option to buy 10,000 ordinary shares at an exercise price of $19.50 and 8,000 restricted stock units (RSUs) each representing one ordinary share. The option and RSUs were reported as acquisitions and are held directly. The option and RSU awards vest in equal quarterly installments over one year, subject to the directors continuous service under the 2017 Equity Incentive Plan. The reporting was filed by an attorney-in-fact on 08/27/2025.

UroGen Pharma Ltd. (URGN) director James A. Robinson Jr. reported grants on 08/26/2025 consisting of a stock option and restricted stock units. The stock option is a right to buy 10,000 ordinary shares at an exercise price of $19.50 per share, exercisable through 08/26/2035. The RSUs represent a contingent right to 8,000 ordinary shares. Both the option shares and RSU shares vest in equal quarterly installments over one year, subject to the director's continuous service under the 2017 Equity Incentive Plan. The Form 4 was signed by an attorney-in-fact on 08/27/2025.

Holden Stuart, a director of UroGen Pharma Ltd. (URGN), received equity awards on 08/26/2025. The Form 4 reports a stock option for 10,000 ordinary shares with a stated price of $19.50 and 8,000 restricted stock units (RSUs), both granted on 08/26/2025. The Form shows 10,000 stock options and 8,000 RSUs beneficially owned following the reported transactions, each held in a direct ownership form. The disclosures state both the option and RSU awards vest in equal quarterly installments over one year, subject to Continuous Service under the 2017 Equity Incentive Plan. The Form 4 is signed by an attorney-in-fact on 08/27/2025.

Cynthia M. Butitta, a director of UroGen Pharma Ltd. (URGN), reported equity awards granted on 08/26/2025. She was granted a stock option to buy 10,000 ordinary shares with an exercise price of $19.50 and a 10-year term expiring 08/26/2035, and 8,000 restricted stock units (RSUs) each convertible into one ordinary share. Both the option and the RSUs were acquired on 08/26/2025 and are held directly.

The option and RSUs vest in equal quarterly installments over one year, conditioned on the director's continued service under the companys 2017 Equity Incentive Plan. The form was signed by an attorney-in-fact on 08/27/2025. The reporting persons address is listed in Princeton, NJ.

UroGen Pharma Ltd. (URGN) director Wen Leana was granted equity awards on 08/26/2025: a stock option for 10,000 ordinary shares with a $19.50 exercise price and 8,000 restricted stock units (RSUs). The option and RSUs vest in equal quarterly installments over one year, subject to the director's continued service under the companys 2017 Equity Incentive Plan. After the grants, the reporting person beneficially owns 10,000 shares underlying the option and 8,000 shares underlying the RSUs, each shown as direct ownership. The Form 4 was signed by an attorney-in-fact on 08/27/2025.